FOURTH CONFERENCE OF

SOCIETY OF TOXICOLOGIC PATHOLOGY -INDIA

"CONTINUING EDUCATION IN TOXICOLOGIC PATHOLOGY – RESPIRATORY AND CARDIOVASCULAR SYSTEM"

ORGANIZED BY: SOCIETY OF TOXICOLOGIC PATHOLOGY - INDIA (STP-I)

NOVEMBER 1-3, 2012



VENUE: "Chancery" The Atria Hotel # 1, Palace Road, Bangalore - 560 001

Society of Toxicologic Pathology - India

29, 1st cross, Malleshwaram, Bangalore - 560 003, Karnataka, India e-mail: stpi.india@gmail.com, Website: http://www.toxpathindia.com



Program overview

Respiratory System (mostly rodents, few lectures on non rodents)

Nasal cavity of rodents and non-rodents (mostly rodents). -anatomy, physiology, histology, pathology (background and drug-related toxicities). – **Dr. Pierre Tellier,** Charles River Laboratories.

Induced changes in Larynx of all species- Dr. Klaus Weber, AnaPath

Role of EM in respiratory toxicity diagnosis. Dr. Klaus Weber, AnaPath

Inhalation toxicity -- lower respiratory tract including pleura and mediastinum.

Respiratory toxicity during oral and other route of drug administration. - Dr. Klaus Weber, AnaPath

Proliferative lesions of respiratory system- Dr. Pierre Tellier, Charles River Laboratories.

Over view of Lung phospholipidosis.- Dr. Pralhad Wangikar, Sai Adventium

Cardiovascular System (Rodents and Dogs/Monkeys)

Structure and function of heart; including sampling of heart for detailed examination for cardiotoxicity- **Dr. Kevin Isaacs,** Consultant in Toxicologic Pathology,

Spontaneous pathology of cardiovascular system in lab animal species- Dr. Kevin Isaacs, Consultant in Toxicologic Pathology

Induced lesions of heart (non proliferative and proliferative)- Dr. C. Gopinath, Consultant in Toxicologic Pathology

Induced lesions of vascular system (non proliferative and proliferative) - Dr. Kevin Isaacs, Consultant in Toxicologic Pathology

Myocardial hypertrophy- Dr. C. Gopinath, Consultant in Toxicologic Pathology

Use of biomarkers for cardiac injury- Dr. Eric Blomme, Abbott Laboratories

Drug induced cardiac conditions and preclinical approaches to predicting them- Dr. Jega Iswaran, Biota Holding Ltd

Drug-induced valvulopathy- Dr. Chandikumar Elangbam, GlaxoSmithKline

General topics

Dr. Peter Mann, Experimental Pathology Laboratories (EPL)- Pathology reporting of preclinical toxicology studies- data integration, issues with pathology reports, regulatory expectations.

Dr. Colin Rousseaux - Colin Rousseaux and Associates, Health product life cycle

Dr. John Finch, Charles River Preclinical Services, Histopathology results: What do they really mean?

Dr. Shashi Ramaiah, Pfizer Pharmaceuticals, Role of biomarkers in preclinical safety evaluation

Dr. Madhav Marathe- Sun Pharma Advanced Research Company Ltd, "Role of QAU in Toxicology, with special reference to Inhalation Toxicology".

Dr. Prem Dua, Consultant in Regulatory Toxicologic Pathology, Evaluations of toxicology/pathology submissions to the FDA

Mr. Edwin Spoelstra, Instech Laboratories, Inc. Continuous Infusion Toxicity Studies in Rats; General Considerations

Dear Colleagues and Guests,

It is a pleasure to invite you to attend Fourth Conference of the Society of Toxicologic Pathology - India on November 1-3, 2012 at Hotel Atria, Bangalore. The theme of the conference is "Continuing Education in Toxicologic Pathology – Respiratory and Cardiovascular System". The organizing committee members have put together extensive three days of technical sessions on toxicology and pathology of Respiratory and Cardiovascular system.

The conference organizers are providing exhibit space for companies offering products and services related to the field of toxicology and toxicologic pathology.

ABOUT BANGALORE

The capital of the state of Karnataka, Bangalore is situated halfway between the east and west coasts in southern India. The city was founded in the 16th century and was ruled by great southern dynasties like the Kadambas, the Hoysalas and Vijayanagar Empire. Legend has it that the name Bangalore comes from "boiled beans" (Benda Kaluru), which was served by a humble old lady to a hungry ruler in the 10th century.

Bangalore is also called "the Garden City" thanks to its many parks and flowering trees. Thanks to many local parks, along with pink cassias, golden acacias, golden tabebuias, blue jacarandas and flaming gul mohars, which bloom throughout the city.

Many international visitors come to Bangalore for its IT industry and prestigious research institutes, such as the Indian Institute of Science, Indian Institute of Management, etc. While enjoying the pleasant weather year-round, tourists can also use the city as a central base for day trips to other Karnataka attractions.

TRANSPORTATION

Bangalore international airport is located at Devanahalli, 35 kilometers from Bangalore City. Most U.S. and many international airlines offer direct flights to Bangalore.

Transportation from the Airport Car Rental

Bangalore International Airport (http://www.bengaluruairport.com) is served by two major car rental firms. Easy Cab - 4343 4343, Meru - 4422 4422, KSTDC- 43464346 24 hour service (Rs 17.50/- per kilometer,). The Citywide public transportation agency is Bangalore Metropolitan Transport Corporation (BMTC).

Local Transportation

Conference organizers will provide transport from Veterinary University guest-house, Karnataka Veterinary Council Guest House and IVRI Guest House.

The Citywide public transportation agency is Bangalore Metropolitan Transport Corporation (BMTC). Auto Rickshaws and City Taxis are other means of transport.

SUBMISSION OF ABSTRACTS FOR YOUNG SCIENTIST AWARD

Professor M. K Shingatgeri Memorial Young Scientist Award is instituted by Dr. Vyas M Shingatgeri, Vice President, Drug Safety Evaluation, Ranbaxy Laboratories Ltd., R&D, Gurgaon, in memory of Late Professor M. K Shingatgeri, Former Dean of Bombay Veterinary College and Professor and Head of the Department of Pharmacology and Toxicology. The award is restricted to the subject/topic of Toxicologic Pathology only. The award consists of a Certificate and cash of Rs. 3000.

All member of the society aged less than 35 years can participate in this competition. Oral presentations shall be for 12 minutes with question and answer session for 3 minutes. The abstract of oral presentation of about 250 words should include title, authors, address, purpose of study, methods, results and conclusions. The name of the presenting author should be underlined. A registered delegate can present a maximum of one original work. Abstract with email address should be submitted preferably through E-mail (not as an attachment file but as a body of the mail) to the Organizing Secretary Dr. Shekar Chelur (E-mail: stpi.india@gmail.com) latest by **October 10, 2012**. Total number of presentations is restricted to eight.


IFSTP STUDENT TRAVEL GRANT

IFSTP (International Federation of Societies of Toxicologic Pathologists) is a confederation of ten national and regional societies of toxicologic pathology (STPs) representing scientists from around the globe. Society of Toxicologic Pathology - India is member of IFSTP. The IFSTP's stated role is to build, integrate and set standards in toxicologic pathology through member societies around the globe. In concordance with their commitment and goals, IFSTP is sponsoring travel grant of USD 500 each (equivalent in INR) for two PhD students who are interested in toxicologic pathology, completing their research work and writing thesis related to toxicologic pathology or in a closely related area. Travel grant is expected to adequately support students travel/accomodation/meeting registration fee. All interested students pursuing their doctoral research should send detailed CV and work report of about 300 words, attested by their Research Guide and Dean of College to the Organizing Secretary, Dr. Shekar Chelur latest by **October 10, 2012.** Poster presentation of research work must be presented at the conference. A panel of experts will evaluate work report and presentation and the winners will be awarded a certificate along with travel grant at an Award ceremony at the conference.

SUBMISSION OF ABSTRACTS FOR BEST POSTER PRESENTATION AWARD

The award is restricted to the subject/topic of Toxicologic Pathology only. The award consists of a Certificate and cash award of Rs. 1500.

The abstract of poster presentation of about 250 words should include title, authors, address, purpose of study, methods, results and conclusions. The name of the presenting author should be underlined. A registered delegate and member of the society can present a maximum of one original work. Abstract with email address should be submitted preferably through E-mail (not as an attachment file but as a body of the mail) to the Organizing Secretary Dr. Shekar Chelur (E-mail: stpi.india@gmail.com) latest by **October 10, 2012**. Total number of presentations is restricted to ten. Poster shall be of size 48 inches (Width) x 36 inches (Height). General template given below may be followed.



SOCIAL EVENTS

All registered participants will receive social event passes for dinners on 1st and 2nd November 2012.

MEETING MATERIALS

All registered attendees can pick up printed program books, badges and social event passes at registration desk.

AWARDS CEREMONY

The Awards Ceremony will take place on November 2. STPI Young Scientist Award recipients and Best Poster presentation award recipients will be recognized at this time.

GENERAL BODY MEETING

The Society - Business Meeting will be held on November 1st evening.

HOTEL INFORMATION

Hotel Reservations

STPI has reserved limited number of rooms at discounted rates at the Hotel Atria, Hotel Ashraya International and Hotel Nandhini. Delegates are requested to contact the hotel directly. Please remember to refer to the "Society of Toxicologic Pathology - India" meeting in order to receive the discounted rates (maximum 20%). It is important to make reservations as soon as possible to assure availability. All cancellations and changes should be made directly with the hotel. **The discounted rates are mentioned below.**

1. The Atria Hotel (Conference venue)

No. 1, Palace Road, Bangalore - 560001

Ph: 91-080-22205205, Fax: 91-080-22256850

Room Tariff: Rs.35,00 (Standard room single) to Rs. 6100 (Lifestyle room double) +

Tax

E-mail: rooms@atriahotel.com Web: www.atriahotel.com

2. Ashraya International Hotel (5 minutes walk)

149 Infantry Road, Bangalore 560 001 Phone: +91-80-40355999, +91-80-22261921, +91-80-51148484, Fax: +91-80-22263982

Room Tariff: Rs. 2400 (Standard room, Single) to Rs. 3200 (Superior room, double) + Tax

Email: ashraya.hotel@gmail.com / booking@ashrayahotel.com Website: www.ashrayahotel.com

3. Hotel Nandhini (15 minutes drive)

164, MLA lay out, R.T Nagar Main Road, Bangalore-560032 Ph: +91 80 22178900 Fax; +91 80 22178951 Email: rooms.nandhinirtn@rediffmail.com Website; www.nandhini.com

Room tariff: Deluxe AC, Rs-1200 (single), Rs -1500 (double), Comfort class - Rs - 1400 (single), Rs -1600 (double)

ACCOMMODATION

Limited accommodation will be available in the Veterinary University guest-house, Karnataka Veterinary Council Guest House and IVRI Guest House on first come/informed basis to the delegates. Average room rates per day on twin sharing basis will be **Rs. 150 to 300**. The rest of the delegates will be assisted in getting accommodation in hotels if they can let us know in advance. For further details, contact Organizing Secretary, Dr. Shekar Chelur at stpi.inida@gmail.com




Eric Blomme, D.V.M., Ph.D., D.A.C.V.P.

Senior Research Fellow, Director, Investigate Toxicology and Pathology, Abbott Laboratories Email: eric.blomme@abbott.com

Eric Blomme received his D.V.M. from The University of Lyon (France), studied Management at McGill University, and completed a residency in Veterinary Pathology at Cornell University and a

Ph.D. at Ohio State University. His areas of expertise include the development of new technologies, in particular genomics, for predictive toxicology and the preclinical safety assessment of new molecular entities using molecular toxicology, genetic toxicology and pathology. Eric joined Abbott in 2003. He is currently Senior Research Fellow, Director of Investigative Toxicology and Pathology in Preclinical Safety and also oversees Cellular, Molecular and Exploratory Toxicology in Discovery. The role of these two groups is to provide predictive, mechanistic and regulatory toxicology data for compounds in discovery and development. In his prior positions at Monsanto/Searle and Pharmacia, Eric worked on various drug discovery and development projects. His publication record includes over 65 peer-reviewed manuscripts, several book chapters and a book (Genomics in Drug Discovery and Development, Wiley). Eric is editor or on the editorial board of several scientific journals and an active member of several professional organizations.



Prem Dua, DVM, PhD

Consultant in Regulatory Toxicologic Pathology, USA Email: pdua34@yahoo.com

Dr. Dua is a graduate of Punjab Veterinary College, Hissar (India) and holds a PhD from Mississippi State University, USA. He has over 30 years of diverse regulatory review experience with the

Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration (FDA), encompassing a wide range of toxicologic pathology issues. He joined the FDA as a staff pathologist and served in various capacities within the Agency including Chief of Diagnostic Pathology, Division Director and as a Sr. Toxicologic Veterinary Pathologist. He provided subject matter expertise in Toxicologic Veterinary Pathology and oversaw regulatory reviews and complex safety evaluations of pathology data received by the FDA for pre-market products' approvals including but not limited to food and color additives, preservatives, artificial sweeteners and biotech products. He served on several FDA committees, providing authoritative expertise in toxicologic veterinary pathology for diagnosing rodent pathologic lesions and evaluating and interpreting rodent toxicity and carcinogenicity studies.

Prior to joining the FDA, Dr. Dua served as a veterinary pathologist and diagnostician for avian and animal disease in Virgina Department of Agriculture, State Diagnostic Laboratory.

Dr. Dua recently retired from the FDA and is now an independent consultant providing specialized expertise in regulatory toxicologic pathology.

Chandi S. Elangbam BVSc, MVSc, PhD, DACVP, DABT Director, Pathophysiology, Safety Assessment, GlaxoSmithKline

Dr. Elangbam is currently a Director of Pathophysiology at GlaxoSmithKline, Research Triangle Park, North Carolina, USA. He provides specialized expertise in early drug discovery programs, animal models of human disease, pathologic evaluation and interpretation of target biological profiling in support of novel drug discovery and development. Previously, Dr. Elangbam has had a variety of roles and positions, including Director, Regulatory and Discovery Pathology (2001-2003), GlaxoSmithKline, Research Triangle Park, North Carolina, USA; Senior Principal Pathologist (1998-2001), GlaxoWellcome, Research Triangle Park, North Carolina, USA; Senior/Staff Pathologist (1991-1998), WIL Research Laboratories Inc.,

Ashland, Ohio, USA; Visiting Instructor, Department of Pathology, Oklahoma State University (1990-1991), Stillwater, Oklahoma, USA; Research Assistant (1982-1985), Toxicology and Pathology Department, CIBA-GEIGY Research Center, Goregaon (East), Bombay, India; and Assistant Professor/Pathologist (1981-1982), Department of Pathology, Bombay Veterinary College, Parel, Bombay, India.

Dr. Elangbam received his B.V.Sc. (1979) and M.V.Sc. (1981) from Bombay Veterinary College, Bombay, India; and completed his Residency and Ph.D. in Veterinary Pathology (1990) from Oklahoma State University, Stillwater, Oklahoma, USA. Dr. Elangbam has specialty boardcertification in Veterinary Pathology (Diplomate, ACVP; 1994) and Toxicology (Diplomate, ABT; 1996). He was in the Editorial board of Toxicologic Pathology (2002-2005). Dr. Elangbam has published more than 53 publications, including invited reviews, and received the Centennial Research Excellence Award, Oklahoma State University, 1990. Presently, his research interests include use of transcriptomic (gene) signals in drug discovery and potential biomarker for drug safety and liabilities of anti-obesity therapeutics.



Peter Mann, DVM, ACVP Manager, Experimental Pathology Laboratories Inc, 2544 13th Ave W, Seattle, WA, USA

Dr. Peter Mann received his AB in English Literature from Washington University in St. Louis in 1970, and his D.V.M. from the University of Missouri in 1979. Following a residency at the National Zoological Park in Washington, D.C., he spent several years on staff at the New Bolton Center at the University of Pennsylvania. He then spent 5 years as a staff pathologist for ICI Americas (now Astra-Zeneca). In 1989, he joined Experimental Pathology Labs (EPL), holding positions in the UK, North Carolina, Maryland, and Seattle, where he currently serves as the manager of EPL NorthWest. His professional interests include peer review, experimental carcinogenesis, respiratory pathology, the use of alternative models in toxicology, liposomes and the pathology of siRNAs. He has written several book chapters and numerous scientific articles. In addition to the STP, he is a member of the AVMA, SOT and an ACVP Diplomate, as well as a passionate bird watcher.




John Finch

Director of Toxicology, Charles River Laboratories, UK

John Finch is a 1977 Edinburgh Veterinary graduate. After working in general Veterinary practice for two years he returned to Edinburgh to study Tropical Veterinary Science and spent five years in what was then North Yemen as a Veterinary Investigation Officer. He joined Charles River Laboratories in Scotland (then

known as Inveresk Research International) as a trainee veterinary pathologist and laboratory animal veterinarian in 1986. He became Head of Pathology in 1993 and in 2005 he was appointed Director of Toxicology with responsibility for toxicology study managers, animal unit staff, and pathology and veterinary services.

He is a former President of the British Laboratory Animals Veterinary Association, the British Society of Toxicological Pathologists and the European Society of Toxicologic Pathology. John was an examiner for the Royal College of Veterinary Surgeons in Laboratory Animal Medicine and for the Royal College of Pathologists in both Laboratory Animal Pathology and Toxicology. John is married, has two grown up children and a grandchild.



Chirukandath Gopinath BVSc; PhD; FRCPath; FIATP Consultant in Toxicology & Pathology, United Kingdom

Dr Gopinath qualified as a veterinarian in 1959 in Kerala, India, briefly worked as a veterinarian in Kerala and joined as a lecturer in veterinary pathology at Kerala Veterinary College in Mannuthy, India. He had worked as a government veterinary officer in British Guiana for 4 years. Took up post graduate research in experimental pathology at Liverpool University in 1966 and worked as a lecturer

in veterinary pathology. In 1974 moved into industry as head of Pathology, drug safety laboratories at Organon in Holland. Dr Gopinath returned to UK to work at Huntingdon Research Centre in various capacities from senior pathologist to director of pathology and chief scientific officer till 2002. From then he worked as an independent consultant. During his career ha has published extensively in peer reviewed journals and have contributed to many books. He is a founder member of BSTP, and past president. Was past president of IFSTP and past director of IATP. Is a member of STP and recipient of achievement award from STP in 2009. Gopinath was chairman of examiners board in veterinary pathology at Royal College of Pathology, London.



Jega Iswaran, PhD, FRCPath

Director, Drug Safety at Biota Holdings Ltd , Melbourne E mail: jiswaran@gmail.com

Dr Jega Iswaran obtained the PhD degree from the University of London. His professional experience in the pharmaceutical industry and regulatory drug development extends to over 30 years. During the period 1972 to 1995, he worked at the major international

company ICI/Zeneca Pharmaceuticals and was based at the Company Headquarters in the United Kingdom, rising to the position of Manager of Pathology. He obtained Board Certification (MRCPath qualification) at this time in Toxicological Pathology from the UK Certifying Authority, The Royal College of Pathologists, and was elected to Fellowship (FRCPath) in 1990. At ICI/Zeneca, his responsibilities covered new products development and safety of medicines. I was actively associated with international regulatory development of products covering the therapeutics areas of: anti-infectives, anti-cancer, CNS, endocrinology, respiratory diseases, gastric diseases and metabolic diseases. As part of presenting our safety evaluation programs and defending product safety, I have visited and interacted with many major international and national regulatory agencies such as FDA, EMEA, MCA/MHRA, BGA, MHW, HPB and other European and Scandinavian agencies. I have acted as company 'Expert' on safety matters for product registration documents at the time of NDAs and MAAs.

In Australia, I have held the positions of Development Director at Antisense Therapeutics Ltd and for the last 6 years as Director, Drug Safety at Biota Holdings Ltd in Melbourne, which is a publicly listed company developing anti-viral agents for respiratory and liver infections.



Kevin Isaacs MA, Vet MB, MRCVS, FRCPath Consultant Toxicologic Pathologist, UK

Kevin Isaacs is a graduate of the Cambridge Veterinary School, having first gained a 1st in Part I of the Tripos exams before completing Part II in Social & Political Sciences. In 1983 he passed the examinations for membership of the Royal College of

Pathologists in Laboratory Animal Pathology. After a two-year spell as a small animal veterinarian, he started life as a toxicological pathologist at Huntingdon Research Centre in 1978. His career developed through positions at ICI Pharmaceuticals, ICI Central Toxicology Laboratory, Smith Kline & French and Experimental Pathology Laboratories (UK), which he ran as Director for 5 years, before becoming an independent consultant in 1994.

Kevin has been President, Chair of the Education sub-committee and webmaster of the British Society for Toxicological Pathology; President and webmaster of the British Society of Veterinary Pathology; Chair of the Specialty Advisory Committee for Veterinary Pathology and Examiner for the Royal College of Pathologists and Chair of the Veterinary Pathology Liaison Group for the Royal College of Veterinary Surgeons. He has spoken at numerous meetings for the BSTP and in various other international meetings over the years.



Madhav R. Marathe

M.V.Sc (Veterinary Pathology), FIBA (UK), cGLP (USA). Vice President, Toxicology and Animal House. Sun Pharma Advanced Research Company Ltd, Vadodara (Gujarat),

Senior most Pre-clinical Toxicologist and Pathologist in India, in New Drug Discovery Research, with 40 year's experience. B. V. Sc

with Honours (1965) and M.V. Sc in Pathology with distinction from Bombay University, Mumabi (1970). Recipient of "Outstanding Scientist of 21st Century Award" with a "Medal of Honour" from Cambridge, England (2007). Diplomate of Indian Board of Toxicologic Pathology (2011). Certification of "Good Laboratory Practice & Quality Assurance" USA (1996). Served as Toxicologist and Pathologist in CIBA-GEIGY, Ranbaxy, Lupin and presently with Sun-Pharma, Vadodara as Vice President (Toxicology and Laboratory Animal Resources). Built "AAALAC" accredited modern Animal house in Sun Pharma (2009). Principal Investigator of Toxicology Studies carried out in USA, UK, Switzerland, Germany, France and Czech Republic. Submitted > 1000 Toxicology studies to US FDA on "First Time Right" basis. Guide to Ph.D. students in Zoology/Toxicology and faculty member in M.S. University, Baroda.



Shashi Ramaiah, PhD, DACVP

Precision Medicine lead and head of Clinical Pathology and Safety Biomarker group, Pfizer Pharmaceuticals, Cambridge, MA E mail: shashi.ramaiah@pfizer.com

Shashi Ramaiah is currently the Precision Medicine lead and head of Clinical Pathology and Safety Biomarker group within Pfizer Inc. Cambridge, MA. Shashi's responsibilities as biomarker head includes scientific leadership and supervision of laboratory operations & personnel aimed at developing innovative and efficient biomarker strategies and providing routine clinical pathology analyses to support animal models evaluations. Additional responsibilities include representing drug safety on project teams, relevant project & issues management teams to provide scientific guidance on biomarker strategies. Precision medicine lead responsibilities include representing project teams from lead selection to POC to ensure translational/precision medicine biomarker strategies are developed through partnerships in discovery, clinical and partner lines.

Shashi Ramaiah's early education was in India where he completed his Veterinary Medicine degree (BVSc) from the University of Agricultural Sciences, Bangalore, India and then completed Masters in Pharmacology and Toxicology (MVSc) from the same University. After couple of years of small animal medicine practice, Shashi migrated to USA in 1995 and completed his PhD (1999) from University of Louisiana at Monroe in Pharmacology and Toxicology. After completing his PhD, Shashi enrolled in the Clinical Pathology residency program at University of Florida (1999-2002) and completed his certification in Veterinary Clinical Pathology in 2002. Following his residency training, Shashi accepted a tenure track faculty position in the department of Veterinary Pathobiology, College of Veterinary Medicine at Texas A&M University. During his ~6 yr stint as a faculty at Texas A&M, Shashi pursued his independent research on an NIH-NIAAA funded research grant on alcoholic hepatitis and non alcoholic fatty liver syndrome. In addition to his research, Shashi participated in diagnostic clinical pathology service, residency training and graduate student teaching at Texas A&M In 2008, Shashi made a career change from academia to Pfizer pharmaceutical University. industry.

Shashi is on the editorial boards of Toxicologic Pathology, International Journal of Toxicology and Veterinary Clinical Pathology journals. Shashi previously served as the secretary of Gulf Coast and Central States regional chapter of the Society of Toxicology and as the Chair of the Continuing Education committee for Society of Toxicologic Pathology. Shashi has published in the areas of toxicology, clinical pathology and biomarkers (>40 peer reviewed manuscripts) and has chaired numerous scientific symposium and workshops at toxicology and pathology meetings. Shashi is also an active member of the Society of Toxicology, American College of Veterinary Pathology and Society of Toxicologic Pathology. Shashi is an adjunct faculty at the College of Veterinary Medicine in Michigan State University and Texas A&M University. As an adjunct faculty at Michigan State University, Shashi serves as a mentor for one of the Pfizer-sponsored ACVP-STP coalition fellows.



Colin G. Rousseaux, PhD, DABT, FRCPath, FIATP, FATS

Principal of Colin Rousseaux and Associates

Adjunct professor in the Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Dr. Rousseaux received his Ph.D. from the University of Saskatchewan in 1985 in the field of toxicologic pathology. He is a Diplomate of the American Board of Toxicology (DABT), a Fellow of the Royal College of Pathologists (FRCPath), Fellow of the International Academy of Toxicologic Pathology (FIATP) and Fellow of the Academy of Toxicologic Sciences (FATS). Dr. Rousseaux is an Adjunct Professor, Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON; and Professeur Associé, Département de Biologie, Université du Québec à Montréal, QC.

Dr. Rousseaux has authored over 85 scientific publications, over 85 abstracts and is the coeditor of "Handbook of Toxicologic Pathology" a standard reference text for pathologists in industrial settings; co-editor of "Fundamentals of Toxicologic Pathology" (Academic Press: 1998; 2nd Edition: 2010), a graduate student text; and co-author of "Bioavailability in Environmental Human Health Risk Assessment" (Lewis Publishers: 1996). He has continued to practice diagnostic and research pathology. In 1992, Dr. Rousseaux was awarded the SmithKline Beecham Award for Research Excellence for his work in developmental toxicologic pathology.

Dr. Rousseaux was President of the Society of Toxicologic Pathology (USA), and is a member of the Executive and Educational Standards Committees, and Chair of the Strategic Planning Committee of this Society and member of Continuing Education Committee, and Annual Symposium Committee. He is also a councilor for the International Federation of Societies of Toxicologic Pathologists. Presently, Dr. Rousseaux is principal of Colin Rousseaux and Associates and is adjunct professor in the Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.



Pierre Tellier, D.V.M., Dip.Path., M.Sc., Diplomate ACVP Executive Director, Pathology Charles River Laboratories, Montreal E mail: Pierre.Tellier@crl.com

Dr. Tellier received his D.V.M. in 1980 and completed a combined internship/M.Sc. in 1983 at the University of Montreal (St-Hyacinthe). He successfully sat for the ACVP exam in 1985. His entire career was spent in Contract Research Organizations (CROs) in North America and Europe. Pierre worked for BioResearch Laboratories from 1982 to 1989 and then spent a few years in France as Director of Pathology in an international CRO. He then moved back to Canada where is acting currently as Executive Director of Pathology at the Charles River Laboratories in Montreal. One of his principal interest in toxicologic pathology is the respiratory system; he has been invited to teach at the BSTP respiratory teaching module and he was also a participant to the INHAND publication on lesions of the rat and mouse Pierre has been heavily involved in mentoring/teaching toxicology respiratory tract. pathologists both within his own organization and externally. He had the chance over the years to be an adjunct or invited professor in North American and European universities to share his knowledge of toxicology pathology with the next generation of veterinary pathologists. He has been an active member of the STP (Society of Toxicologic Pathology) since he joined in 1988; he was elected councilor of the Executive Committee of the STP in 2011. Pierre is a member of several international Toxicology Pathology associations including the American College of Veterinary Pathologists, the European Society of Toxicologic Pathology, the French Society of Toxicologic Pathology and the Japanese Society of Toxicologic Pathology.



Pralhad B. Wangikar, M.V.Sc. Ph.D. DABT, Associate Director, Preclinical, Sai Advantium Pharma Ltd., Pune.India

Presently Associate Director Toxicology at Sai Advantium Pharma Ltd in Pune, India; in this function he is responsible for Toxicology and Vivarium.

Dr. Pralhad Wangikar has completed his Bachelor and Masters (BVSc & AH and MVSc) in Veterinary Pathology from College of Veterinary and Animal Sciences, MAU, Parbhani and Doctorate (PhD) in Veterinary Pathology from Indian Veterinary Research Institute (IVRI) Izatnagar Bareilly, UP, India.

1997 he started his career as Veterinary Pathologist at Intox, Institute for Toxicological studies, Pune India. 1998 moved to College of Veterinary and Animal Sciences MAU Parbhani as a Assistant Professor where he was involved in teaching the Pathology courses to Undergraduate students. Jan 2003 he joined as a research scientist at Ranbaxy Research Laboratories, Gurgaon India from this position he moved to Dhirubhai Ambani Reliance Life Sciences Centre, Navi Mumbai, India in Aug 2005. There he was responsible to establish histopathology and clinical pathology laboratories standardized the toxicity studies and achieved the GLP certificate.



Klaus Weber. DVM, PhD AnaPath Gmbh , Switzerland

Klaus Weber was born in East Germany and became a veterinarian and a biologist. He was working in laboratories in East Germany and also, for several years in human pathology. With over 25 years of professional experience in human and animal pathology. Weber was since 1991 head of pathology at RCC/Harlan Laboratories.

Klaus Weber has experience in all laboratory species including fish and invertebrates. His area of work covers short and long term as well as oncogenicity studies with specialties in neuropathology, inhalation pathology, bone marrow differentiation and various other topics. He founded in 2004 AnaPath Gmbh in Switzerland, a holding covering nowadays ten independent pathologists.

FOURTH CONFERENCE OF SOCIETY OF TOXICOLOGIC PATHOLOGY - INDIA

"CONTINUING EDUCATION IN TOXICOLOGIC PATHOLOGY – RESPIRATORY AND CARDIOVASCULAR SYSTEM" - NOVEMBER 1-3, 2012 "CHANCERY" THE ATRIA HOTEL # 1, PALACE ROAD, BANGALORE - 560 001

REGISTRATION FORM

Name:	
Designation:	
Address:	
Phone / Fax:	_E-mail:
STP-I membership #:	Amount:
Draft/cheque No. :	Bank:

Date:	Signature:	
Registration fee	Before October 1	Spot registration fee
STP–I member	Rs. 4000	Rs. 4500
Non member	Rs. 5000	Rs. 5500
Students	Rs. 2500	

Online transfer details: Axis Bank Ltd, Electronic City, A/C name: **Society of Toxicologic Pathology – India,** A/C # 912010024584538, IFS Code: UTIB0000677. Intimation of online transfer with filled registration form e-mailed to <u>stpi.india@gmail.com</u>

At par cheque/draft to be drawn in favour of **Society of Toxicologic Pathology** – **India** (STP–I), payable at Bangalore sent to Dr. Shekar Chelur, Aurigene Discovery Technologies Ltd. 39–40, KIADB Industrial Area, Electronics City Phase II, Hosur Road, Bangalore – 560 100, Phone (O): 080–28521314, Mobile: +91 98802 37237